The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.
May 6th 2024
Darolutamide uptake in metastatic hormone-sensitive prostate cancer has become routine both in doublet and triplet regimens in community urology practices.
Medical Crossfire®: Critical Questions on Diagnosis, Sequencing, and Selection of Systemic and Radioligand Therapy Options for Patients with GEP-NETs
View More
Medical Crossfire®: Expert Exchanges to Maximize Clinical Outcomes for Patients with CRPC Through Evidence-Based Personalized Therapy
View More
Everything You Need to Know About PARP Inhibitor Combinations in Prostate Cancer Care: Why? For Whom? And When?
View More
Advances In™: Targeting PSMA to Advance Diagnosis And Management Of Patients With Prostate Cancer
View More
Clinical Case Vignette Series: Integrating Recent Data into Practice to Improve Outcomes in Advanced Prostate Cancer
View More
Community Practice Connections™: Controversies and Conversations About HER2- Expressing Breast Cancer…Advances in Management of HER2-Low to -Positive Disease
View More
2023 ASCO Direct™ Highlights: Practice-Changing Data From the Leading Oncology Conference
View More
Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Medical Crossfire®: Where Are We in the World of ADCs? From HER2 to CEACAM5, TROP2, HER3, CDH6, B7H3, c-MET and Beyond!
View More
Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer
View More
Dialogues With the Surgeon on Integration of Systemic Therapies in Perioperative Settings for NSCLC: Looking at EGFR, ALK, IO, and Beyond…
View More
Tumor-Infiltrating Lymphocyte Therapy Advances Into Melanoma
View More
FDA Approves Pluvicto for Progressive, PSMA-Positive Metastatic CRPC
The FDA has approved lutetium Lu 177 vipivotide tetraxetan for the treatment of adult patients with prostate-specific membrane antigen–positive metastatic castration-resistant prostate cancer who have previously received other anticancer therapies.
Axel S. Merseburger, MD, discusses the safety and efficacy results from the phase 3b PRESIDE trial examining continued enzalutamide treatment with docetaxel in select patients with metastatic castration-resistant prostate cancer who had progressed on enzalutamide monotherapy and the significance of the data for the treatment paradigm.
Radiotherapy Treatments Are Getting Shorter and Faster in Prostate Cancer
The history of radiation therapy for men with prostate cancer extends back more than a century. From those early crude methods, the field has advanced to delivery potentially curative therapies that can be administered in as little as 2 weeks.
Phase 3 KEYLYNK-010 Trial Examining Pembrolizumab/Olaparib in mCRPC to Stop for Futility
The phase 3 KEYLYNK-001 trial evaluating the combination of pembrolizumab and olaparib in patients with metastatic castration-resistant prostate cancer who progressed following chemotherapy and either abiraterone acetate or enzalutamide will be discontinued for futility.
Eleni Efstathiou, MD, PhD, discussed the combination of niraparib and abiraterone acetate and prednisone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations, results from the MAGNITUDE trial, and next steps for research.
Bavdegalutamide Showcases Early Activity in Metastatic Castration-Resistant Prostate Cancer
The novel androgen receptor PROTAC degrader, bavdegalutamide, was found to be clinically active and tolerable with manageable adverse effects in patients with metastatic castration-resistant prostate cancer.
Niraparib Demonstrates Antitumor Activity in Heavily Pretreated mCRPC With BRCA Mutations
The PARP inhibitor niraparib elicited a meaningful overall response rate in patients with heavily pretreated metastatic castration-resistant prostate cancer and DNA repair gene defects, particularly those with BRCA alterations.
Continuous Enzalutamide After Progression Improves PFS in Patients with mCRPC
February 18th 2022Continuous enzalutamide plus docetaxel and prednisone elicited progression-free survival improvement vs placebo with docetaxel and prednisone in patients with metastatic castration-resistant prostate cancer who had previously progressed on enzalutamide alone
Darolutamide Plus ADT Boosts OS in Metastatic Castration-Sensitive Prostate Cancer
February 18th 2022The addition of darolutamide to androgen deprivation therapy and docetaxel generated better overall survival vs placebo with ADT and docetaxel in patients with metastatic castration-sensitive prostate cancer.
Frontline Niraparib Plus Abiraterone Improves rPFS in HRR Gene–Altered mCRPC
February 17th 2022The combination of niraparib and abiraterone acetate and prednisone led to a significant improvement in radiographic progression-free survival vs placebo plus abiraterone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations.
Olaparib/Abiraterone Combo Significantly Improves Radiographic PFS in mCRPC
Olaparib in combination with abiraterone acetate led to a 34% reduction in the risk of radiographic disease progression or death compared with placebo and abiraterone as a first-line treatment for patients with metastatic castration-resistant prostate cancer, according to results of the phase 3 PROpel trial.